Because it appears that I am the only one at SI who follow REGN (and is SH), i will continue to respond to myself...
Maybe better Qs here is, what is an SNY interest/incentive to invest in Ablynx so called nano-bodies, while ignoring REGN HL-Abs?
For instance, after licensing REGN Abs platform, they developed their own IL-4/IL-13 dual neutralizing Abs for IPF (and some other indications, allergic...). Ab NEVER came close to any activity relative to Dupi activity. I guess, science is not that simple after all.
None is to claim that LAG3/GITR/CTLA-4 will prove to be viable second IO drug in IO combo, none is to claim (science is so fragile and fast evolving in absence of the true knowledge) that any IO-IO will prove to be better than some other non-IO combination, none is to claim that hold upper hand (not even MRK with Keytruda) in future cancer fields, ...but IF one do not try, IF one do not speculate, IF one do not experiment...it has chance less than ZERO to make any impact. Confidence in that "IF" is what separate one bios from another, IMO.
I am positive (with some confidence) that REGN will from RGC efforts *map* cancer bio-marker field that may give them better chance on "IF"!
Cheers! |
